Business Context and Reporting Period
Company: Kindly MD, Inc. (Ticker: KDLY)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Kindly MD is a pain management clinic and healthcare data company focused on reducing opioid use through integrated medical and behavioral health services. The company recently completed an Initial Public Offering (IPO) on June 3, 2024, transitioning from a private entity to a public company listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Total Revenues | $639,057 | $1,468,086 |
| Net Loss | $(1,319,653) | $(1,601,979) |
| Loss Per Share (Basic & Diluted) | $(0.26) | $(0.33) |
| Cash and Cash Equivalents (End of Period) | $4,740,006 | |
| Working Capital | $4,111,725 | |
| Net Cash Used in Operating Activities | N/A | $(1,126,976) |
| Net Cash Provided by Financing Activities | N/A | $5,352,664 |
| Total Debt (Notes Payable, Net) | $228,061 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 34.8% ($340,481) for the three months ended June 30, 2024, compared to the same period in 2023. This is primarily due to a strategic shift from cash-pay patient services to insurance billing (Medicare, Medicaid, commercial payers), which has a longer reimbursement cycle.
- Increased Operating Loss: Net loss for the three months ended June 30, 2024, increased to $1.32 million from $596,408 in the prior year period. This was driven by higher interest expenses ($318,450 vs. $8,194) due to debt discount amortization and a loss on debt extinguishment.
- Liquidity Transformation: Cash and cash equivalents surged from $525,500 at December 31, 2023, to $4.74 million at June 30, 2024. This increase is directly attributable to the IPO completed in June 2024, which generated approximately $5.9 million in net proceeds.
- Debt Restructuring: The company repaid all outstanding 10% OID promissory notes totaling $463,534 upon the IPO. In exchange, note holders received cash and 80,808 shares of restricted common stock, extinguishing a derivative liability of $214,949.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management asserts that the IPO proceeds provide sufficient liquidity to meet obligations for at least the next 12 months. The company has moved from a "going concern" uncertainty to a position of adequate cash reserves.
- Strategic Shift: The company is actively transitioning its revenue model to rely more heavily on insurance reimbursements rather than direct cash payments. While this caused a short-term revenue dip, it is intended to create more sustainable, long-term cash flow.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024. The company does not currently maintain sufficient controls to ensure timely and accurate reporting.
- Risks: Key risks include the need for additional capital if operations do not generate sufficient cash flow, reliance on third-party suppliers, and the inherent uncertainties of the healthcare regulatory environment.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the timeline for insurance reimbursements to understand the lag between service delivery and cash collection as the company shifts away from cash-pay models.
- Internal Control Remediation: Monitor future filings for updates on the remediation plan regarding the ineffective disclosure controls and procedures.
- Warrant Dilution: Review the terms of the 2.7 million outstanding warrants (exercise price $6.33) issued during the IPO and their potential impact on future share count and earnings per share.
- Debt Obligations: Confirm the remaining terms and interest rates on the $228,061 of notes payable and any new financing arrangements.
- Insurance Payer Mix: Assess the growth rate of reimbursements from Medicare, Medicaid, and commercial payers to validate the strategic pivot's success.